Literature DB >> 9373574

Fewer bone histomorphometric abnormalities with intermittent than with continuous slow-release sodium fluoride therapy.

C M Schnitzler1, J R Wing, F J Raal, M T van der Merwe, J M Mesquita, K A Gear, H J Robson, R Shires.   

Abstract

To help resolve the uncertainty whether sodium fluoride (NaF) therapy should be given intermittently or continuously, we examined iliac crest bone biopsies (before and after treatment) and fragility fracture rates in 35 intermittently treated (group I) and 69 continuously treated (group C) patients; all received calcium. The following statistically significant results were obtained. Reduction in vertebral fracture rate was similar in the two groups. Trabecular thickness and the structurally more important mineralized thickness increased only in group I. Group I also accumulated less excess osteoid (surface, volume). Mean osteoid thickness did not change in either group because of a bimodal distribution of wide seams with osteoblasts and double tetracycline labels, and thin seams without osteoblasts or labels. Osteoid was lamellar. Osteoid in abnormal sites (within bone marrow or bone, or around osteocytes) was found less frequently in group I. Adjusted apposition rate declined and mineralization lag time increased in both groups because of extended unlabelled osteoid seams. Erosion surface increased only in group C. Hook and/or tunnel erosion was seen less frequently in group I; it was closely associated with osteoid in abnormal sites and correlated with osteoid surface. Extended osteoid surface may have forced osteoclasts to hollow out trabeculae, leaving the empty osteoid shell in marrow. Excess osteoid volume and eroded surface and osteoid and erosion in abnormal sites correlated with bone fragility in group C. We conclude that intermittent therapy is to be preferred because it (1) increased mineralized trabecular thickness, (2) did not cause excessive osteoid accumulation and erosion, (3) showed less osteoid and erosion in abnormal sites and (4) led to a similar reduction in the vertebral fracture rate as did continuous treatment. The question of whether intermittency of therapy has some other effect independent of the cumulative dose of fluoride administered cannot be answered by this study.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9373574     DOI: 10.1007/bf01623781

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  29 in total

1.  A model of vertebral trabecular bone architecture and its mechanical properties.

Authors:  K S Jensen; L Mosekilde; L Mosekilde
Journal:  Bone       Date:  1990       Impact factor: 4.398

2.  The effect of sodium fluoride on trabecular architecture.

Authors:  J E Aaron; M C de Vernejoul; J A Kanis
Journal:  Bone       Date:  1991       Impact factor: 4.398

3.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

4.  Fluoride content in human iliac bone: results in controls, patients with fluorosis, and osteoporotic patients treated with fluoride.

Authors:  G Boivin; M C Chapuy; C A Baud; P J Meunier
Journal:  J Bone Miner Res       Date:  1988-10       Impact factor: 6.741

5.  [Results of long-term treatment of primary osteoporosis with sodium fluoride (author's transl)].

Authors:  H P Kruse; F Kuhlencordt; J D Ringe
Journal:  Dtsch Med Wochenschr       Date:  1978-02-10       Impact factor: 0.628

6.  Treatment of osteoporosis with fluoride, calcium, and vitamin D.

Authors:  D Briancon; P J Meunier
Journal:  Orthop Clin North Am       Date:  1981-07       Impact factor: 2.472

7.  Variations in strength of vertebrae with age and their relation to osteoporosis.

Authors:  G H Bell; O Dunbar; J S Beck; A Gibb
Journal:  Calcif Tissue Res       Date:  1967

8.  Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.

Authors:  C Nagant de Deuxchaisnes; J P Devogelaer; G Depresseux; J Malghem; B Maldague
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

9.  Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.

Authors:  C Y Pak; B Adams-Huet; K Sakhaee; N H Bell; A Licata; C Johnston; B Rubin; S Bonnick; V Piziak; H Graham; J Ballard; R Berger; W Fears; N Breslau; C Rubin
Journal:  J Bone Miner Res       Date:  1996-02       Impact factor: 6.741

10.  Clinical trial of fluoride therapy in postmenopausal osteoporotic women: extended observations and additional analysis.

Authors:  B L Riggs; W M O'Fallon; A Lane; S F Hodgson; H W Wahner; J Muhs; E Chao; L J Melton
Journal:  J Bone Miner Res       Date:  1994-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.